...
首页> 外文期刊>European journal of dermatology: EJD >Human immunodeficiency virus type 1 (HIV-1) derived vectors: safety considerations and controversy over therapeutic applications.
【24h】

Human immunodeficiency virus type 1 (HIV-1) derived vectors: safety considerations and controversy over therapeutic applications.

机译:人类1型免疫缺陷病毒(HIV-1)衍生载体:安全性考虑和治疗应用方面的争议。

获取原文
获取原文并翻译 | 示例
           

摘要

The latest generation of lentiviral vectors based on HIV-1 is one of the most efficient tools for gene transduction of mammalian cells. However, the possible employment of HIV-based vectors in clinical trials is a very controversial issue, mainly due to safety and ethical concerns. HIV-1 is a lethal pathogenic agent, which induces AIDS. Genetic vectors must derive either from viruses that are not pathogenic in humans, or that eventually just cause mild illnesses. Patients exposed to HIV-based vectors will test seropositive to certain components of HIV-1. In addition, there might be other possible adverse effects in patients that cannot be predicted, as manyaspects of the pathogenesis of AIDS have not been completely understood yet. On these grounds, it seems necessary to improve the design of other lentiviral vectors, which derive from viruses that are not pathogenic in humans and are distantly related to primate retroviridae. Copyright John Libbey Eurotext 2003.
机译:基于HIV-1的最新一代慢病毒载体是用于哺乳动物细胞基因转导的最有效工具之一。然而,主要由于安全和道德考虑,在临床试验中可能使用基于HIV的载体是一个非常有争议的问题。 HIV-1是致命的致病菌,可诱发AIDS。遗传载体必须来源于对人类无致病性的病毒,或者最终仅导致轻度疾病的病毒。暴露于基于HIV的载体的患者将对HIV-1的某些成分进行血清反应阳性。此外,由于尚未完全了解艾滋病的发病机理,因此可能会对患者产生其他可能无法预测的不良反应。基于这些理由,似乎有必要改善其他慢病毒载体的设计,这些慢病毒载体源自对人类无致病性并且与灵长类逆转录病毒科有密切关系的病毒。版权所有John Libbey Eurotext 2003。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号